Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 - Novartis announced today positive topline results from twice-yearly* Leqvio® ( inclisiran ) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol ...
| Ticker |
Sentiment |
Impact |
|
ALNY
|
Neutral
|
2 %
|
|
META
|
Neutral
|
2 %
|
